INTI
What one share of Inhibitor Therapeutics holds
Pharmaceutical Preparations
February 2026, with support from Frameshift Management, Inc. (“Frameshift”), we submitted a formal meeting request and briefing materials to the U.S. Food and Drug Administration (“FDA”) regarding our proposed development pathway for itraconazole in
Inhibitor Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.02 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.00 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | $0.01 | — | −$0.03 | — | −$0.01 |
| 2013 | $0.00 | −$0.10 | — | −$0.07 | — | −$0.04 |
| 2014 | $0.00 | −$0.04 | — | −$0.01 | — | — |
| 2015 | $0.00 | −$0.02 | — | −$0.01 | — | $0.00 |
| 2016 | $0.00 | −$0.02 | — | −$0.01 | — | $0.02 |
| 2017 | $0.00 | −$0.01 | — | −$0.01 | — | $0.00 |
| 2018 | $0.00 | −$0.01 | — | −$0.01 | — | $0.00 |
| 2019 | $0.00 | −$0.01 | — | −$0.01 | — | −$0.01 |
| 2020 | $0.00 | −$0.00 | — | −$0.00 | — | −$0.01 |
| 2021 | $0.00 | −$0.00 | — | −$0.00 | — | −$0.01 |
| 2022 | — | $0.03 | — | $0.03 | — | — |
| 2023 | — | −$0.02 | — | −$0.02 | — | $0.03 |
| 2024 | — | −$0.02 | — | −$0.02 | — | $0.01 |
| 2025 | — | −$0.02 | — | −$0.02 | — | −$0.01 |